RxDoctor Payments Data

Leah Furman, NP

Family · Post Falls, IDNPI 1487385506

Payments from drug & device makers

$926in general payments, 2019–2025

Across 25 payments — averaging $37.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$259
  • Sequel Med Tech, LLC$142
  • Novo Nordisk$125
  • Amgen$60
  • Dexcom, Inc.$57
  • BETA Bionics, Inc.$50
  • plus $233 from 9 others

What the payments were for

  • Food & beverage$926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$926 in reported general payments places this provider in the 70th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$397
Medicare patients
29
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$42,897
MounjaroTirzepatide11$15,531
Varenicline Tartrate14$1,850
Estradiol (Once Weekly)Estradiol15$1,142
Duloxetine Hcl20$692
Omeprazole39$627
Gabapentin55$626
Doxepin Hcl12$557
Atorvastatin Calcium39$494
Estradiol12$471
Tizanidine Hcl15$459
Potassium Chloride11$451
Rosuvastatin Calcium52$451
Albuterol Sulfate HfaAlbuterol Sulfate22$403
Losartan Potassium44$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$42,89729 claims
Lilly USA, LLCMounjaro$41$15,53111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 809 family providers in Idaho.

Other family in Post Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →